Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 11, 2012, Pages 1339-1346

  Gruver, Aaron M ^a   Amin, Mahul B ^a,e   Luthringer, Daniel J ^a,e   Westfall, Danielle ^a,e   Arora, Komal ^a,e   Farver, Carol F ^a   Osunkoya, Adeboye O ^f   Mckenney, Jesse K ^g   Hansel, Donna E ^a,b,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Glickman Urological and Kidney Institute   (United States)

^c Taussig Cancer Institute   (United States)

^d Genomic Medicine Institute   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 20; CYTOKERATIN 7; DESMOGLEIN 3; DSG3 PROTEIN, HUMAN; GATA3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UPK3A PROTEIN, HUMAN; UROPLAKIN 3;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER INVASION; CELL DIFFERENTIATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; DESMOGLEIN 3; DIAGNOSIS, DIFFERENTIAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-14; KERATIN-20; KERATIN-7; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROPLAKIN III;

EID: 84870860776     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0575-OA     Document Type: Article

References (21)

1. Amin MB. Histological variants of urothelial carcinoma: Diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22(suppl 2):S96- S118.
2. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 7.
3. Martin JE, Jenkins BJ, Zuk RJ, Blandy JP, Baithun SI. Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol. 1989;42(3):250-253.
4. Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol. 2007; 31(12):1777-1787.
5. Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117-122.
6. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int. 1999;62(2):69-75.
7. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27(1):1-10.
8. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147(5):1383-1397.
9. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31(5):673-680.
10. Harnden P, Southgate J. Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol. 1997;50(12):1032- 1033.
11. Savci-Heijink CD, Kosari F, Aubry MC, et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol. 2009;174(5): 1629-1637.
12. Coleman JF, Hansel DE. Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder. Adv Anat Pathol. 2009;16(2):67-78.
13. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and merkel cell carcinomas. Mod Pathol. 1995;8(4):384-388.
14. Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001;10(1):77-82.
15. Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37(5):542-546.
16. Wu RL, Osman I, Wu XR, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res. 1998;58(6):1291-1297.
17. Ordonez NG. Value of thrombomodulin immunostaining in the diagnosis of transitional cell carcinoma: a comparative study with carcinoembryonic antigen. Histopathology. 1997;31(6):517-524.
18. Tamura A, Hebisawa A, Hayashi K, et al. Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung. Lung Cancer. 2001;34(3):375-382.
19. Ogawa H, Yonezawa S, Maruyama I, et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett. 2000;149(1-2):95-103.
20. Hamatake M, Ishida T, Mitsudomi T, Akazawa K, Sugimachi K. Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res. 1996;2(4):763-766.
21. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88(8): 1229-1233.